ReachMD
GI Insights CMEEpisodes
Episodes of GI Insights CME
Mark All
Search Episodes...
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of H
Host: Yelena Janjigian, MD Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence sug
Host: Yelena Janjigian, MD Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence sug
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of H
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of H
Host: Elizabeth Smyth, MD Guest: Jaffer Ajani, MD HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limit
Host: Neilanjan Nandi, MD Guest: Jean-Frederic Colombel, MD There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the comp
Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or secon
Host: Neilanjan Nandi, MD Guest: Sunanda Kane, MD, MSPH, AGAF Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenari
Host: Neilanjan Nandi, MD Guest: Russell D. Cohen, MD, FACG, AGAF New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and D
Host: Neilanjan Nandi, MD Guest: Gary R. Lichtenstein, MD, FACG, FACP, AGAF Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, r
Host: Neilanjan Nandi, MD Guest: Miguel Regueiro, MD, AGAF Treat-to-target is the current standard for the management of IBD, and as such it is imperative to understand what those targets are, what strategies will help you achieve them
Host: Edward Chu, MD Guest: Michael J. Overman, MD Recent immunotherapy approvals have changed the treatment paradigm for first and subsequent lines of treatment for patients with microsatellite-high or mismatch repair deficient metast
Guest: Bincy P. Abraham, MD, MS Guest: Jason Ken Hou, MD, MS, FACG Guest: Siddharth Singh, MD As the most common extraintestinal complication from IBD, iron deficiency anemia (IDA) can take a heavy toll on your patients’ quality of l
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us